Our Compound
We invented a compound, ANS-858, which is an orally bioavailable, selective, reversible ALDH2 inhibitor. Currently, ANS-858 is in preclinical development.
ANS-858 was selected from over 1000 compounds chemically synthesized as apart of our drug discovery program.
Molecular binding of our prototype inhibitor with the enzyme ALDH2
Product Pipeline
ANS-858 works to inhibit ALDH2 which reduces self-administration of various addictive chemicals including alcohol, nicotine, cocaine, and opiates. Currently our research focuses on alcohol use disorder.
| Indication | Product | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| Alcohol Use Disorder | ANS-858 |
|
|||
|
Smoking Cessation Opioid Use Disorder Stimulant Use Disorder |
|||||
Breaking free from harmful cravings
Addiction is compulsive drug seeking behavior in spite of the negative consequences.
People who develop a substance use disorder commonly also suffer from other mental health disorders, such as anxiety. Our research has demonstrated that inhibition of ALDH2 reduces anxiety-like behavior in multiple models, consistent with its effect on mid-brain dopaminergic neurons. These results indicate that ANS-858 may exhibit anti-drinking and anti-anxiety activity and would be novel more complete addition to existing toolkit of therapies and treatments.
X-ray crystal structure of ALDH2